InventisBio is a Shanghai, China–based clinical-stage biotech focused on discovering and developing proprietary small-molecule drugs for cancer and metabolic diseases. Led by Dr. Yaolin Wang (Chairman and CEO), the company currently has three drug candidates in mid- to late-stage clinical development and one new candidate that recently entered a global Phase I study. Its lead programs include D-0502, an oral selective estrogen receptor degrader (SERD) and antagonist for hormone receptor–positive breast cancer, and BPI-D0316, a third-generation EGFR-T790M tyrosine kinase inhibitor. BPI-D0316's China rights have been out-licensed to Betta Pharma and the product is undergoing registration trials for first- and second-line treatment of EGFR-mutated non-small cell lung cancer. The company is also developing D-0120 for gout. Plans include advancing current programs through Phase II studies in China and the United States and expanding the product pipeline and team. InventisBio is a clinical-stage biotech led by Dr. Yaolin Wang focused on discovering and developing novel therapeutics against cancer and metabolic diseases. The company has three drug candidates in clinical development for breast cancer, lung cancer and gout. It licensed China rights to its third-generation EGFR‑T790M inhibitor D‑0316 to Betta Pharma in December 2018 and is co-developing D‑0316 in a phase 2 trial for non-small cell lung cancer. InventisBio intends to use the new funds to accelerate development of its clinical candidates into phase 2 trials and to advance other drug candidates into the clinic. Prior financings noted in the articles include angel investment from Beautiful Mind Capital, a Series A led by Lilly Asia Venture in 2016 and a Series B led by OrbiMed Asia with participation from LAV in 2017. InventisBio is a Shanghai-based biotech dedicated to the discovery and development of novel medicines. Its pipeline includes small-molecule drug candidates for targeted therapies in lung cancer, breast cancer and gout. The company is also developing agents intended to be combined with immune-oncology targeted therapies such as PD-1 antibodies. Three drug candidates were expected to enter Phase 1 clinical trials in the US and China in 2017. InventisBio was co-founded by Chairman and CEO Dr. Yaolin Wang and other scientists with prior experience at Merck and Schering-Plough. Prior financings and the recent Series B provide capital to advance its preclinical and early-clinical programs.

Total raised

$236M

Funding rounds

3

Latest round

Series D

Latest activity

Sep 2020